IKT INHIBIKASE THERAPEUTICS INC Management Changes 8-K Filing 2025 - Management Changes On April 11, 2025, Garth Lees-Rolfe resigned as CFO of Inhibikase Therapeutics, and David McIntyre was appointed as the new CFO on April 14, 2025, with a salary of $485,000 and stock options totaling 3,142,967 shares.Get access to all SEC 8-K filings of the INHIBIKASE THERAPEUTICS INC